TrialInternational journal of clinical oncology2020

Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial.

Kohei Shitara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.